- Home
- BMRC vs RIGL Comparison
BMRC vs RIGL Comparison
Compare BMRC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRC
- RIGL
- Stock Information
- Founded
- BMRC 1989
- RIGL 1996
- Country
- BMRC United States
- RIGL United States
- Employees
- BMRC N/A
- RIGL N/A
- Industry
- BMRC Major Banks
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- BMRC Finance
- RIGL Health Care
- Exchange
- BMRC Nasdaq
- RIGL Nasdaq
- Market Cap
- BMRC 394.5M
- RIGL 366.5M
- IPO Year
- BMRC N/A
- RIGL 2000
- Fundamental
- Price
- BMRC $21.92
- RIGL $17.96
- Analyst Decision
- BMRC Strong Buy
- RIGL Buy
- Analyst Count
- BMRC 3
- RIGL 5
- Target Price
- BMRC $28.00
- RIGL $36.80
- AVG Volume (30 Days)
- BMRC 66.1K
- RIGL 243.6K
- Earning Date
- BMRC 04-28-2025
- RIGL 03-04-2025
- Dividend Yield
- BMRC 4.56%
- RIGL N/A
- EPS Growth
- BMRC N/A
- RIGL N/A
- EPS
- BMRC N/A
- RIGL 0.99
- Revenue
- BMRC $67,983,000.00
- RIGL $179,278,000.00
- Revenue This Year
- BMRC $63.26
- RIGL $14.19
- Revenue Next Year
- BMRC $9.68
- RIGL $13.10
- P/E Ratio
- BMRC N/A
- RIGL $17.88
- Revenue Growth
- BMRC N/A
- RIGL 54.71
- 52 Week Low
- BMRC $14.11
- RIGL $7.48
- 52 Week High
- BMRC $27.11
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- BMRC 37.63
- RIGL 35.87
- Support Level
- BMRC $21.56
- RIGL $19.81
- Resistance Level
- BMRC $22.94
- RIGL $19.97
- Average True Range (ATR)
- BMRC 0.81
- RIGL 1.09
- MACD
- BMRC 0.00
- RIGL -0.27
- Stochastic Oscillator
- BMRC 18.84
- RIGL 21.53
About BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.